RNS

Released : May 01, 2019 07:00   RNS Number : 6577X MaxCyte, Inc. 01 May 2019           MaxCyte Presents at 22 nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing   -   CARMA drug candidates can be manufactured via streamlined,
May 01, 2019
Released : April 24, 2019 07:00   RNS Number : 8683W MaxCyte, Inc. 24 April 2019         MaxCyte, Inc. ("MaxCyte" or the "Company")   MaxCyte Reports Final Results for Year Ended 31 December 2018   ¾  First CARMA™ cell therapeutic programme targeting treatment of solid tumours has advanced into
Apr 24, 2019
Released : April 08, 2019 07:00   RNS Number : 3613V MaxCyte, Inc. 08 April 2019       MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte® Launches ExPERT™ Instrument Family to Provide a Unifying Technology Platform from Concept to Commercialization for Next-Generation Cellular Therapies
Apr 08, 2019
Released : March 26, 2019 07:00   RNS Number : 9554T MaxCyte, Inc. 26 March 2019       MaxCyte, Inc. ("MaxCyte" or the "Company")   Notice of Full Year Results     Gaithersburg, Maryland - 26 March 2019:   MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, will be
Mar 26, 2019
Released : March 19, 2019 17:05   RNS Number : 3554T MaxCyte, Inc. 19 March 2019       MaxCyte, Inc. ("MaxCyte" or the "Company")   Director Dealings Issue of Equity   Gaithersburg, Maryland - 19 March 2019:   MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Mar 19, 2019
Released : March 01, 2019 07:00   RNS Number : 5188R MaxCyte, Inc. 01 March 2019           MaxCyte, Inc. ("MaxCyte" or the "Company")   MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company     Gaithersburg, Maryland - 01 March 2019:   MaxCyte (LSE: MXCT, MXCS),
Mar 01, 2019
Released : February 26, 2019 17:32   RNS Number : 1971R MaxCyte, Inc. 26 February 2019   THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR
Feb 26, 2019
Released : February 05, 2019 16:32   RNS Number : 1641P MaxCyte, Inc. 05 February 2019   THIS ANNOUNCEMENT IS RESTRUCTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH
Feb 05, 2019
Released : February 05, 2019 07:00   RNS Number : 0847P MaxCyte, Inc. 05 February 2019   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION
Feb 05, 2019
Released : March 05, 2019 07:00   RNS Number : 8081R MaxCyte, Inc. 05 March 2019           MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options   Maryland, USA - 05 March 2019 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company , announces that on 04
Feb 05, 2019